Source: International Congress 2014 – Pulmonary hypertension: clinical management
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Urushibara, N. Tanabe, R. Suda, F. Kato, H. Kasai, A. Sekine, R. Nishimura, T. Jujo, T. Sugiura, S. Sakao, Y. Kasahara, K. Tatsumi (Chiba, Japan). Examination about what determine quality of life (QOL) and the association between QOL and therapeutic intervention for patients with chronic thromboembolitic pulmonary hypertension (CTEPH). Eur Respir J 2014; 44: Suppl. 58, 2383

Member's Comments

No comment yet.

Related content which might interest you: Correlations between clinical variables and quality of life in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 A retrospective study of depressive illness in patients with pulmonary hypertension (PH) at a specialist centre Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Portuguese validation of the Cambridge pulmonary hypertension outcome review (CAMPHOR) questionnaire Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Global burden of chronic thromboembolic pulmonary hypertension (CTEPH): An epidemiological analysis Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Quality of life of patients with pulmonary arterial hypertension associated with congenital heart disease: The multicenter cross-sectional ACHILLE study Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Effect of pulmonary-specific vasodilator therapy in patients with chronic obstructive pulmonary disease and pulmonary hypertension. A retrospective analysis Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 PAH-specific therapies improve survival in patients with pulmonary arterial hypertension associated with connective tissue diseases: A Russian single centre experience Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Pulmonary hypertension correction in patients with chronic obstructive pulmonary disease and essential hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Characteristics of patients with pulmonary hypertension in end stage renal disease Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 HbA1c-levels in patients with operable chronic thromboembolic pulmonary hypertension Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 EmPHasis-10 is associated with clinical outcome measures in pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 LATE-BREAKING ABSTRACT: Riociguat for the treatment of chronic thromboembolic pulmonary hypertension (CTEPH): 2-year results from the CHEST-2 long-term extension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014 Studying quality of life in PAH: Patient-reported outcome assessment and psychosocial evaluation in a 6 months follow-up Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Prognostic value of outcome variables at follow-up in patients with PAH Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Effect of pulmonary hemodynamics on the prognosis of patients with emphysematous COPD after LVRS Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 CT measured pulmonary artery to aorta ratio as a predictor of pulmonary hypertension in COPD Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Impact of riociguat on health-related quality of life (HRQoL) in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 The influence of psycho-social factors in the evolution of pulmonary hypertension patients Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Effects of riociguat in patients with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary endarterectomy (PEA) Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014